Reassuring Market Adoption of Daybue Fuels Acadia's Strategic Advancements, Analysts Boost Price Targets

By: via Benzinga
Acadia Pharmaceuticals Inc(NASDAQ: ACAD) expanded its current licensing agreement for trofinetide withNeuren ...
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.